New York Genome Center
- Company typePrivate
- Founded2011
- HeadquartersNew York, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
New York Genome Center firmographics
Firmographics- Name
- New York Genome Center
- Legal name
- New York Genome Center, Inc.
- Website
- https://nygenome.org
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
New York Genome Center industry classification
Industry- Product category
- Genomics Research Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)
- akta.pro secondary industries
- Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
Keywords
Where New York Genome Center is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
New York Genome Center business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Genomics and Bioinformatics Services: NYGC provides sequencing and bioinformatics services to the academic and scientific communities. Pricing is quote-based as outlined in service agreements. Results are provided for research purposes only.
- Research Grants and Funding: As a nonprofit academic research institution (501(c)(3)), NYGC receives significant funding from government agencies (NIH grants totaling $143M under management as of 12/2025), private foundations (The Warren Alpert Foundation, The Mark Foundation, etc.), and individual donors.
- Clinical Genetic Testing: State-of-the-art clinical diagnostic laboratory utilizing next-generation sequencing technology for cutting-edge genetic tests in genetics and oncology. CLIA-certified and licensed in all 50 U.S. states and D.C.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Monthly | Quote-based service pricing for academic and industry clients |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
New York Genome Center product offering
Product offeringCore offering
NYGC provides genomic sequencing, bioinformatics analysis, and CLIA-certified clinical genetic testing services to academic, medical, and industry clients. The organization operates advanced technology platforms for next-generation sequencing, single-cell profiling, and CRISPR-based research while running collaborative research programs in cancer genomics (Polyethnic-1000), neurodegenerative disease (ALS Consortium), and neuropsychiatric disease. NYGC develops and distributes proprietary computational tools (Lancet2, Cas13design, PrecisionChain) and novel methodologies (D&D-seq, scG2P, PATH) for the scientific community.
Product overview
NYGC operates as a multi-institutional hub for collaborative genomic research, offering a portfolio of genomics services and internally developed tools. The core offerings include a CLIA-accredited Clinical Genetics Laboratory for diagnostic testing, Research Sequencing services, and Technology Development platforms including Computational Biology. Key products include Cas13design (RNA-targeting CRISPR guide RNA design tool), PrecisionChain (blockchain-based data sharing platform), and Lancet2 (variant detection software). NYGC also conducts collaborative research through initiatives like Polyethnic-1000 (cancer genomics in diverse populations) and the ALS Consortium. The institution develops specialized methodologies such as D&D-seq (single-cell DNA-protein mapping), PATH (tumor plasticity quantification), and scG2P (single-cell mutation mapping) through its faculty labs.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Genetics Laboratory CLIA-accredited clinical diagnostic laboratory providing cutting-edge genetic testing services in genetics and oncology using next-generation sequencing technology. Licensed in all 50 U.S. states and D.C. and participates in CAP proficiency testing. Serves healthcare providers and clinical laboratories requiring state-of-the-art clinical genetic testing and precision medicine capabilities.
- Research Sequencing Advanced sequencing services providing whole genome and targeted sequencing for academic and research institutions. Supports collaborative research programs across multiple disease areas with 195K+ Whole Genome Equivalents Sequenced to date. Priced via quotation with results provided for research purposes only.
- Technology Development Multidisciplinary team developing innovative genomic tools and technologies including novel sequencing methods, CRISPR applications, and computational pipelines. Drives NYGC's proprietary method development including D&D-seq, scG2P, and other breakthrough approaches.
- Computational Biology Lab Technology platform providing computational biology expertise and bioinformatics capabilities to support genomic research, including data analysis, algorithm development, and biological interpretation. Led by Senior Vice President of Informatics Dr. Michael Zody.
- Polyethnic-1000 Collaborative research initiative advancing cancer genomics in diverse populations, studying cancers in minority patients including bladder, pancreatic, breast, prostate, colon, endometrial, and lung cancers. Funded by The Mark Foundation for Cancer Research, Illumina Inc., and other philanthropic supporters.
- ALS Consortium Multi-institutional collaboration focused on ALS research and care, working with Target ALS, ALS United Greater New York, Eleanor and Lou Gehrig ALS Center at Columbia University, and academic medical centers. Led by Dr. Hemali Phatnani, Director of the Center for Genomics of Neurodegenerative Disease.
- Cas13design Web-based tool and open-source platform for designing optimized Cas13 guide RNAs to target RNA transcripts. Integrates machine learning-based predictive models for guide efficiency across human transcriptome, model organisms, and viral RNA genomes. Available as web tool and open-source toolbox for the research community.
- PrecisionChain Blockchain-based data sharing and analysis platform for precision medicine that securely stores, harmonizes, shares, integrates, and analyzes both genetic and clinical data. Uses OMOP Common Data Model and Variant Call Format (VCF) for data harmonization. Provides interactive Jupyter Notebooks for analysis.
- Lancet2 Open-source computational method that significantly improves detection of somatic variants across the genome. Uses local assembly and joint analysis of tumor and matched normal sequencing data with explainable machine learning for variant scoring. Achieves ~10x speed improvement and 50% memory reduction versus original Lancet.
- D&D-seq (Docking and Deaminase Sequencing) Single-cell method for mapping DNA-protein interactions. Uses antibodies to bring a DNA-editing enzyme close to target proteins, allowing researchers to record where proteins interact with DNA. First method easily incorporated into high-throughput single-cell multi-omics workflows enabling combined genome, transcriptome, and proteome analyses.
- scG2P (single-cell Genotype-to-Phenotype) Single-cell profiling technique that maps pre-malignant gene mutations in solid tissues for the first time. Analyzes clonal driver mutations in esophageal tissue samples and other solid tissues, enabling cancer researchers to study tumor evolution at single-cell resolution.
- PATH (Phylogenetic Analysis of Trait Heritability) Analytical tool to quantify tumor cell plasticity, measuring how tumor cells 'shape-shift' to become more aggressive and treatment-resistant. Identifies key transitional cell states in cancer progression using lineage information (DNA markers) and cell state data from gene activity, surface receptors, or spatial locations.
Quantifiable outcome
- 195K+ Whole Genome Equivalents Sequenced
- +3 more outcomes
Companies that use New York Genome Center
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles3 records
New York Genome Center technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability12 records
Feature9 records
New York Genome Center partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered core and minor.
- Mission Bio Inc.coreCollaboration with Weill Cornell Medicine and Mission Bio Inc. to develop the scG2P single-cell profiling technique that maps pre-malignant gene mutations in solid tissues. Published in Cancer Discovery journal. Mission Bio provides single-cell technology expertise for the research initiative.
- Weill Cornell MedicinecorePrimary collaborative research partner with joint faculty appointments. Multiple joint research programs including cancer research, Landau Lab studies on cancer detection from blood tests, bladder cancer genomics with Dr. Bishoy Faltas, and computational biology collaborations.
- Target ALScoreNYGC ALS Consortium collaborates with Target ALS on ALS research initiatives. Dr. Hemali Phatnani serves as Director of NYGC's Center for Genomics of Neurodegenerative Disease and works with Target ALS to develop treatments for ALS.
- Columbia UniversitycoreFounding institutional member with multiple joint faculty appointments. Dr. Bing Ren holds joint appointment as professor in Departments of Genetics and Development, Biochemistry and Molecular Biophysics, and Systems Biology. Dr. Gamze Gürsoy holds appointment as Herbert Irving Assistant Professor of Biomedical Informatics at Columbia.
- Cold Spring Harbor LaboratorycoreFounding institutional member collaborating on Polyethnic-1000 cancer genomics research initiative. Joint research on pancreatic cancer, colorectal cancer, and endometrial cancer disparities in minority populations.
- New York UniversitycoreFounding institutional member with joint faculty appointments. Dr. Neville Sanjana holds appointment as Associate Professor of Biology at NYU. Dr. Rahul Satija is Associate Professor at NYU's Center for Genomics and Systems Biology. Joint CRISPR technology development through Sanjana Lab.
- ALS United Greater New YorkminorCollaboration on NYGC ALS Consortium contributing to New York State Governor's proposed $25 million ALS research and care program.
- Memorial Sloan Kettering Cancer CentercoreFounding institutional member participating in Polyethnic-1000 cancer genomics initiative, including multiple myeloma research in collaboration with NYU.
- Northwell HealthminorFounding institutional member contributing to Polyethnic-1000 collaborative cancer research projects including pancreatic cancer and endometrial cancer disparity studies.
- The Rockefeller UniversitycoreFounding institutional member supporting collaborative genomic research across NYGC's research programs.
- Icahn School of Medicine at Mount SinaiminorFounding institutional member collaborating on Polyethnic-1000 research, including breast and prostate cancer disparity studies.
- Stony Brook UniversitycoreFounding institutional member contributing to NYGC's collaborative research ecosystem.
- NewYork-Presbyterian HospitalcoreFounding institutional member supporting cancer research and clinical care collaborations with NYGC.
- Eleanor and Lou Gehrig ALS Center at Columbia UniversityminorPartner in NYGC ALS Consortium contributing to New York State Governor's proposed $25 million ALS research and care program.
- University of Rochester Medical CenterminorPartner in NYGC ALS Consortium contributing to New York State Governor's proposed $25 million ALS research and care program.
- BC Cancer Research InstituteminorDr. Samuel Aparicio serves as Senior Scientific Director of Cancer Genomics at NYGC while maintaining position at BC Cancer. Joint research on breast tissue aging and cancer risk published in Nature Aging.
- University of CambridgeminorInternational research collaboration with Dr. Samuel Aparicio on breast tissue aging study published in Nature Aging.
- Brown UniversityminorCollaboration on single-cell data privacy risk quantification study with researchers from Columbia University and Brown University.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
New York Genome Center competitors and assessment
Company assessmentMarket position
Strengths5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
New York Genome Center social profiles
Digital presenceNew York Genome Center compliance and trust
Trust signalCompliance3 records
New York Genome Center financial estimates
Financial estimateRevenue estimate
Valuation estimate
New York Genome Center leadership team
Management profileNumber of profiles
Profiles13 records
New York Genome Center funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
New York Genome Center M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about New York Genome Center
What does New York Genome Center do?
NYGC provides genomic sequencing, bioinformatics analysis, and CLIA-certified clinical genetic testing services to academic, medical, and industry clients. The organization operates advanced technology platforms for next-generation sequencing, single-cell profiling, and CRISPR-based research while running collaborative research programs in cancer genomics (Polyethnic-1000), neurodegenerative disease (ALS Consortium), and neuropsychiatric disease. NYGC develops and distributes proprietary computational tools (Lancet2, Cas13design, PrecisionChain) and novel methodologies (D&D-seq, scG2P, PATH) for the scientific community.
Is New York Genome Center a public or private company?
New York Genome Center is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was New York Genome Center founded?
New York Genome Center was founded in 2011. It employs 101 to 250 people.
Where is New York Genome Center based?
New York Genome Center is headquartered in New York, United States, in the North America region.
How does New York Genome Center make money?
Three revenue lines are on record. Genomics and Bioinformatics Services are the primary driver. The others are research Grants and Funding and clinical Genetic Testing.
Does New York Genome Center have an API?
No public API is recorded for New York Genome Center.
What industry is New York Genome Center in?
New York Genome Center's product category is Genomics Research Services. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 621511 and its SIC code is 8731.